Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL ALLERGY SINUS vs ALAWAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
Treatment of ocular itching associated with allergic conjunctivitis
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (Cr Cl <30 m L/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency.
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Not extensively metabolized in the eye; systemic metabolism by hepatic CYP450 enzymes is minimal due to low systemic absorption.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination.
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Approximately 65-75% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Vd: 1.0-1.5 L/kg, indicating extensive distribution into total body water and tissues; high penetration into ocular tissues and respiratory mucosa.
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
Oral: ~50% due to first-pass metabolism (CYP3A4 and P-glycoprotein). Ophthalmic solution: negligible systemic absorption (<0.5% of topical dose). Intravenous: 100%.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
No dosage adjustment required. Sodium cromoglicate is primarily excreted unchanged in urine, but no specific GFR-based adjustments are recommended due to wide safety margin.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
No dosage adjustment required. Sodium cromoglicate is minimally metabolized and undergoes biliary excretion; however, no specific Child-Pugh based modifications are established.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Children 2-5 years: 1 spray per nostril every 6-8 hours as needed. Children 6 years and older: same as adult (2 sprays per nostril every 12 hours). Maximum 2 doses per nostril per day in all age groups. Weight-based dosing not established.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
No specific dose adjustment required; use same adult dose. Caution in elderly with renal impairment due to potential accumulation, though clinical significance is minimal.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
None
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
For topical ophthalmic use only,Do not inject,Contact lens wearers should remove lenses before instillation and wait at least 10 minutes before reinserting,May cause temporary blurred vision,Avoid touching dropper tip to any surface to prevent contamination
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Hypersensitivity to cetirizine or any component of the formulation
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
No specific food interactions with Alaway ophthalmic solution. Take as directed, regardless of meals. Avoid rubbing eyes after application.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, skeletal abnormalities) at maternally toxic doses (≥ 30 mg/kg/day in rats, 68 times the maximum recommended human intranasal dose). There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data; avoid use unless necessary due to lack of safety evidence.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
Azelastine is excreted in human breast milk; the milk-to-plasma ratio (M/P) is unknown. In a study of intranasal azelastine (2 sprays per nostril twice daily), the estimated daily infant dose via breast milk is 0.7% of the maternal dose, which is considered low. However, due to the potential for adverse effects in nursing infants (e.g., somnolence, irritability), caution is advised. Use only if clearly needed and benefit outweighs risk. Consider alternative therapies with more safety data.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
No specific dose adjustments are recommended for pregnancy. However, pharmacokinetic changes during pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may reduce azelastine systemic exposure; the clinical significance is unknown. Use the lowest effective dose for the shortest duration. Maximum recommended intranasal dose: 2 sprays per nostril twice daily (total 548 mcg/day). Avoid exceeding this dose.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Alaway (ketotifen fumarate ophthalmic solution) is used for prevention of itching associated with allergic conjunctivitis. It is a mast cell stabilizer with antihistamine properties. Onset of action occurs within minutes, but may require several days of use for full effect. Advise patients to avoid wearing contact lenses if eyes are red. Remove contacts before instillation and wait at least 10 minutes before reinserting.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before using this medication; wait at least 10 minutes after using drops before reinserting.,Use as directed, typically one drop in each affected eye twice daily, with at least 6-8 hours between doses.,Do not use while wearing contact lenses if eyes are red or irritated.,Temporary burning or stinging may occur upon instillation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL ALLERGY SINUS vs ALAWAY, answered by our medical review team.
ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. ALAWAY is a Ophthalmic Antihistamine that works by ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL ALLERGY SINUS and ALAWAY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. The standard adult dose of ALAWAY is: 2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL ALLERGY SINUS and ALAWAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . ALAWAY is classified as Category C. ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.